NO20053204L - Substituerte dihydrofenantridinsulfonamider. - Google Patents

Substituerte dihydrofenantridinsulfonamider.

Info

Publication number: NO20053204L
Authority: NO; Norway
Prior art keywords: dihydrophenanthrine; sulfonamides; substituted; arthritis; diseases
Prior art date: 2002-12-04

Application number

NO20053204A

Other languages

English (en)

Norwegian (no)

Other versions

NO20053204D0 (no

Inventor

Mark Anthony Ashwell

Albert John Molinari

William Jay Moore

Brian Hugh Ridgway

Amedeco Arturo Failli

Original Assignee

Wyeth Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-04

Filing date

2005-06-30

Publication date

2005-09-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32474616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20053204(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-06-30 Application filed by Wyeth Corp filed Critical Wyeth Corp

2005-06-30 Publication of NO20053204D0 publication Critical patent/NO20053204D0/no

2005-09-05 Publication of NO20053204L publication Critical patent/NO20053204L/no

Links

229940124530 sulfonamide Drugs 0.000 title 1
150000003456 sulfonamides Chemical class 0.000 title 1
206010003246 arthritis Diseases 0.000 abstract 2
201000001320 Atherosclerosis Diseases 0.000 abstract 1
208000023275 Autoimmune disease Diseases 0.000 abstract 1
206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
206010019280 Heart failures Diseases 0.000 abstract 1
208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000002757 inflammatory effect Effects 0.000 abstract 1
201000006417 multiple sclerosis Diseases 0.000 abstract 1
208000010125 myocardial infarction Diseases 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/10—Aza-phenanthrenes
- C07D221/12—Phenanthridines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Neurology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Rheumatology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Immunology (AREA)
Hospice & Palliative Care (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO20053204A 2002-12-04 2005-06-30 Substituerte dihydrofenantridinsulfonamider. NO20053204L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US43094902P	2002-12-04	2002-12-04
US10/718,461 US6894061B2 (en)	2002-12-04	2003-11-20	Substituted dihydrophenanthridinesulfonamides
PCT/US2003/038290 WO2004050631A1 (fr)	2002-12-04	2003-12-02	Dihydrophenanthridinesul fonamides substitues

Publications (2)

Publication Number	Publication Date
NO20053204D0 NO20053204D0 (no)	2005-06-30
NO20053204L true NO20053204L (no)	2005-09-05

Family

ID=32474616

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20053204A NO20053204L (no)	2002-12-04	2005-06-30	Substituerte dihydrofenantridinsulfonamider.

Country Status (19)

Country	Link
US (1)	US6894061B2 (fr)
EP (1)	EP1567502B1 (fr)
JP (1)	JP4465280B2 (fr)
KR (1)	KR20050085321A (fr)
AT (1)	ATE370934T1 (fr)
AU (1)	AU2003298819A1 (fr)
BR (1)	BR0316196A (fr)
CA (1)	CA2508329A1 (fr)
CR (1)	CR7854A (fr)
DE (1)	DE60315874T2 (fr)
DK (1)	DK1567502T3 (fr)
EC (1)	ECSP055832A (fr)
ES (1)	ES2291739T3 (fr)
MX (1)	MXPA05006003A (fr)
NO (1)	NO20053204L (fr)
NZ (1)	NZ540440A (fr)
RU (1)	RU2005118070A (fr)
TW (1)	TW200510322A (fr)
WO (1)	WO2004050631A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050119276A1 (en) *	2003-09-24	2005-06-02	Wyeth	Methods of treating inflammatory bowel disease using NF-kB inhibitors
US20050113405A1 (en) *	2003-09-24	2005-05-26	Wyeth	Methods of treating rheumatoid arthritis using NF-kB inhibitors
EP1652841A1 (fr) *	2004-04-30	2006-05-03	Switch Biotech Aktiengesellschaft	Dérivés de phénanthridine comme inhibiteurs d' hyperprolifération des cellules T et/ou kératinocytes
CN1968932A (zh) *	2004-06-18	2007-05-23	惠氏公司	制备6－烷基－5－芳基磺酰基－二氢菲啶的方法
US7304073B2 (en) *	2004-08-20	2007-12-04	Wyeth	Method of treating myocardial ischemia-reperfusion injury using NF-kB inhibitors
BRPI0514860A (pt) *	2004-09-02	2008-06-24	Wyeth Corp	fenóis de fenantridina carbonila
US7555415B2 (en)	2005-01-19	2009-06-30	Wyeth	Methods for the design of estrogen receptor ligands
HU230518B1 (hu) *	2005-12-20	2016-10-28	Richter Gedeon Nyrt.	Bradykinin B1 receptor szelektív antagonista hatással rendelkező új fenatridin származékok, eljárás előállításukra, és az ezeket tartalmazó gyógyszerkészítmények
TW200829578A (en)	2006-11-23	2008-07-16	Astrazeneca Ab	Chemical compounds 537
JO2754B1 (en)	2006-12-21	2014-03-15	استرازينكا ايه بي	Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders
TW200848021A (en)	2007-03-06	2008-12-16	Wyeth Corp	Sulfonylated heterocycles useful for modulation of the progesterone receptor
ES2569660T3 (es)	2007-06-08	2016-05-12	Mannkind Corporation	Inhibidores de la IRE-1alfa
US8211930B2 (en)	2008-05-20	2012-07-03	Astrazeneca Ab	Phenyl and benzodioxinyl substituted indazoles derivatives
EP3209641A4 (fr)	2014-05-05	2018-06-06	Lycera Corporation	Benzènesulfonamido et composés apparentés utilisés en tant qu'agonistes de ror et pour le traitement de maladie
US9896441B2 (en)	2014-05-05	2018-02-20	Lycera Corporation	Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
EP3292119A4 (fr)	2015-05-05	2018-10-03	Lycera Corporation	SULFONAMIDES DE DIHYDRO-2H-BENZO[B][1,4]OXAZINE ET COMPOSÉS APPARENTÉS DESTINÉS À ÊTRE UTILISÉS COMME AGONISTES DE RORy ET POUR LE TRAITEMENT DE MALADIES
AU2016276947A1 (en)	2015-06-11	2017-12-14	Lycera Corporation	Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
WO2020117894A1 (fr) *	2018-12-05	2020-06-11	The Board Of Trustees Of The University Of Illinois	Alcaloïdes d'isocarbostyrile et leur fonctionnalisation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1135947A (en)	1965-04-20	1968-12-11	Aspro Nicholas Ltd	Novel biologically active derivatives of phenanthridone
CA2066132A1 (fr)	1991-04-16	1992-10-17	Thomas A. Rano	2-phenanthridonylcarbapenemes
EP0509756A1 (fr)	1991-04-16	1992-10-21	Merck & Co. Inc.	Carbapénèmes 2-phénanthridonyles contenant des substituants cationisables
US5153185A (en)	1991-04-16	1992-10-06	Merck & Co., Inc.	2-phenanthridonyl carbapenems
US5726186A (en)	1995-09-08	1998-03-10	Eli Lilly And Company	Pentacyclic compounds, intermediates, processes, compositions, and methods
US6121279A (en)	1997-07-25	2000-09-19	Byk Gulden Lomberg Chemische Fabrik Gmbh	Substituted 6-phenylphenanthridines
ATE312081T1 (de)	1999-01-15	2005-12-15	Altana Pharma Ag	6-phenylphenanthridine mit pde-iv hemmender wirkung
US6534518B1 (en)	1999-01-15	2003-03-18	Altana Pharma Ag	Polysubstituted 6-phenylphenanthridines with PDE-IV inhibiting activity
US6531464B1 (en)	1999-12-07	2003-03-11	Inotek Pharmaceutical Corporation	Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives
AU2001281965A1 (en)	2000-07-14	2002-01-30	Byk Gulden Lomberg Chemische Fabrik G.M.B.H.	Novel 6-phenylphenanthridines
AU2001288623A1 (en)	2000-09-05	2002-03-22	Tularik, Inc.	Fxr modulators

2003
- 2003-11-20 US US10/718,461 patent/US6894061B2/en not_active Expired - Fee Related
- 2003-12-02 ES ES03796577T patent/ES2291739T3/es not_active Expired - Lifetime
- 2003-12-02 NZ NZ540440A patent/NZ540440A/en unknown
- 2003-12-02 MX MXPA05006003A patent/MXPA05006003A/es active IP Right Grant
- 2003-12-02 RU RU2005118070/04A patent/RU2005118070A/ru not_active Application Discontinuation
- 2003-12-02 CA CA002508329A patent/CA2508329A1/fr not_active Abandoned
- 2003-12-02 AT AT03796577T patent/ATE370934T1/de not_active IP Right Cessation
- 2003-12-02 WO PCT/US2003/038290 patent/WO2004050631A1/fr active IP Right Grant
- 2003-12-02 BR BR0316196-0A patent/BR0316196A/pt not_active IP Right Cessation
- 2003-12-02 JP JP2004557494A patent/JP4465280B2/ja not_active Expired - Fee Related
- 2003-12-02 KR KR1020057010047A patent/KR20050085321A/ko not_active Ceased
- 2003-12-02 AU AU2003298819A patent/AU2003298819A1/en not_active Withdrawn
- 2003-12-02 EP EP03796577A patent/EP1567502B1/fr not_active Expired - Lifetime
- 2003-12-02 DK DK03796577T patent/DK1567502T3/da active
- 2003-12-02 DE DE60315874T patent/DE60315874T2/de not_active Expired - Lifetime
- 2003-12-04 TW TW092134185A patent/TW200510322A/zh unknown
2005
- 2005-06-02 EC EC2005005832A patent/ECSP055832A/es unknown
- 2005-06-02 CR CR7854A patent/CR7854A/es not_active Application Discontinuation
- 2005-06-30 NO NO20053204A patent/NO20053204L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
NZ540440A (en)	2006-11-30
EP1567502B1 (fr)	2007-08-22
EP1567502A1 (fr)	2005-08-31
CA2508329A1 (fr)	2004-06-17
KR20050085321A (ko)	2005-08-29
DE60315874T2 (de)	2008-05-15
DE60315874D1 (de)	2007-10-04
NO20053204D0 (no)	2005-06-30
CR7854A (es)	2006-04-28
ECSP055832A (es)	2005-08-11
JP2006510631A (ja)	2006-03-30
US20040167155A1 (en)	2004-08-26
US6894061B2 (en)	2005-05-17
RU2005118070A (ru)	2006-01-27
AU2003298819A1 (en)	2004-06-23
DK1567502T3 (da)	2007-10-29
TW200510322A (en)	2005-03-16
JP4465280B2 (ja)	2010-05-19
MXPA05006003A (es)	2005-08-18
ES2291739T3 (es)	2008-03-01
BR0316196A (pt)	2005-09-27
ATE370934T1 (de)	2007-09-15
WO2004050631A1 (fr)	2004-06-17

Legal Events

Date	Code	Title	Description
2007-08-27	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
ATE370934T1 (de)	2007-09-15	Substituierte dihydrophenanthridin-sulfonamide
MXPA05011581A (es)	2005-12-14	Derivados de acido 3-(1-naftil)-2-cianopropanoico como ligandos receptores de estrogenos.
EA200500017A1 (ru)	2005-06-30	Новые соединения
CY1111225T1 (el)	2015-06-11	Νεα πεπτιδια ως αναστολεις πρωτεασης νs3-σερινης ιου ηπατiτιδας c
TR200201187T2 (tr)	2002-08-21	Ters transkriptazın inhibitörleri olarak benzofenonlar
NO20053470L (no)	2005-09-02	Triazolopyridaziner som proteinkinase-inhibitorer
BR0314475A (pt)	2005-08-09	Substituìdos 4-(indazol-3-il) fenóis como ligandos de receptor de estrogênio (er) e seu uso no tratamento de doenças inflamatórias
MX2010003612A (es)	2010-04-30	Derivados de oxadiazol.
NO20062950L (no)	2006-08-23	5,7-diaminopyrazolo `43-Dlpyrimidiner med PDE-5 inhiberende aktivitet
ITMI20030709A1 (it)	2003-10-13	Miscele di stabilizzanti.
DE602004008098D1 (de)	2007-09-20	Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
NO20083743L (no)	2008-11-19	Pyrimidinylsulfonamidforbindelser som inhiberer leukocyttadhesjon mediert av VLA-4
DK1940826T3 (da)	2011-04-18	Pyrimidinylamidforbindelser, der inhiberer leukocytadhæsion medieret gennem BLA-4
MX2010003614A (es)	2010-04-21	Compuestos de diarilo oxadiazol.
DK1507775T3 (da)	2009-05-11	Heterocykliske forbindelser som hæmmer leukocyt-adhæsion medieret af alfa-4-integriner
ATE240328T1 (de)	2003-05-15	Substituierte azaoxindolederivate
NO20070089L (no)	2007-01-05	DPP-IV inhibitorer
EA201070779A1 (ru)	2011-02-28	Триазолсодержащие производные оксадиазола
EA200500803A1 (ru)	2005-10-27	Антагонисты ccr1 для лечения воспалительных артритов, демиелинизационных воспалительных заболеваний
MXPA05007607A (es)	2005-09-30	Inhibidores amida y ester de la metaloproteinasa de matriz.
DE60015508T2 (de)	2005-04-21	C-16 ungesätigte fp-selektive prostaglandin analoge
EA200400438A1 (ru)	2004-10-28	Применение ирбесартана для изготовления лекарств, которые пригодны для предупреждения или лечения лёгочной гипертонии
AU7122501A (en)	2002-02-05	Aryl sulfonamides as serotonin antagonist for the treatment of obesity
PT1334094E (pt)	2005-05-31	Benzo[b]tiofenos e benzo(d)isotiazoles para diminuir o colesterol
BRPI0415355A (pt)	2006-12-12	triarilimidazóis